U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H17N3S.2ClH.H2O
Molecular Weight 302.264
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRAMIPEXOLE DIHYDROCHLORIDE

SMILES

O.Cl.Cl.CCCN[C@H]1CCC2=C(C1)SC(N)=N2

InChI

InChIKey=APVQOOKHDZVJEX-QTPLPEIMSA-N
InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0.../s1

HIDE SMILES / InChI
Molecular Formula C10H17N3S
Molecular Weight 211.327
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020667s014s017s018lbl.pdf

Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum. Pramipexole is used for the treatment of signs and symptoms of idiopathic Parkinson's disease.

CNS Activity

Originator

Approval Year

1997
189
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 1.5 nM [EC50]
Agonist
2752
 27.0 nM [EC50]
Agonist
2752
 15.0 nM [EC50]
Inhibitor
8504
 4.81 µM [IC50]
Inhibitor
8504
 5.37 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
MIRAPEX

Approved Use

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Launch Date

1997
Primary
Approved
8583
MIRAPEX

Approved Use

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.268 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/20110012
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.29 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/20110012
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
31.2 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/20110012
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 61.6
Health Status: unhealthy
Age Group: 61.6
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Disc. AE: Hallucination, Hypotension...
AEs leading to
discontinuation/dose reduction:
Hallucination (1.3%)
Hypotension (0.5%)
Peripheral edema (0.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Disc. AE: Hallucinations, Sleepiness...
AEs leading to
discontinuation/dose reduction:
Hallucinations (4.3%)
Sleepiness (3%)
Dizziness (2.5%)
Memory loss (1.2%)
Paranoia (0.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
DLT: Drowsiness, Muscle spasms...
Dose limiting toxicities:
Drowsiness (3.6%)
Muscle spasms (1.8%)
Insomnia (1.8%)
Vertigo (1.8%)
Ankle swelling (1.8%)
Hallucination (3.6%)
Nausea (1.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Disc. AE: Hallucination, Peripheral edema...
AEs leading to
discontinuation/dose reduction:
Hallucination (1%)
Peripheral edema (0.8%)
Abdominal pain upper (0.6%)
Myocardial infarction (0.6%)
Nausea (0.6%)
Pneumonia (0.6%)
Vomiting (0.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
AEs

AEs

AESignificanceDosePopulation
Hypotension 0.5%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 61.6
Health Status: unhealthy
Age Group: 61.6
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Peripheral edema 0.5%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 61.6
Health Status: unhealthy
Age Group: 61.6
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Hallucination 1.3%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 61.6
Health Status: unhealthy
Age Group: 61.6
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Paranoia 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Memory loss 1.2%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Dizziness 2.5%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Sleepiness 3%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Hallucinations 4.3%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Ankle swelling 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Insomnia 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Muscle spasms 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Nausea 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Vertigo 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Drowsiness 3.6%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Hallucination 3.6%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Abdominal pain upper 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Myocardial infarction 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Nausea 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Pneumonia 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Vomiting 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Peripheral edema 0.8%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Hallucination 1%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:8356
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8356
ChemicalBook
CB0486178
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0486178
eMolecules
6843675
https://www.emolecules.com/cgi-bin/more?vid=6843675
MolPort
MolPort-003-849-957
https://www.molport.com/shop/molecule-link/MolPort-003-849-957
Selleck Chemicals
Pramipexole-Mirapex
http://www.selleckchem.com/products/Pramipexole-Mirapex.html
ZINC
ZINC000003781664
http://zinc15.docking.org/substances/ZINC000003781664
PubMed

PubMed

TitleDatePubMed
Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor.
2003-11-21
Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.
2003-11
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
2003-10-08
Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
2003-10
Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum.
2003-10
Current treatment options for restless legs syndrome.
2003-10
Clinical strategies to prevent and delay motor complications.
2003-09-23
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
2003-09
Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms.
2003-08-15
Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.
2003-08-08
Current status of Parkinson's disease treatment in Korea.
2003-08
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists.
2003-07
Parkinson's disease: is the initial treatment established?
2003-07
Dual dopamine agonist treatment in Parkinson's disease.
2003-07
Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.
2003-07
Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.
2003-07
Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment.
2003-06
[Treatment of restless legs syndrome in uremic patients undergoing dialysis with pramipexole: preliminary results].
2003-06
Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
2003-06
The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption--a nation-wide perspective in Sweden.
2003-06
Efficacy, safety and cost of new drugs acting on the central nervous system.
2003-05
Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists.
2003-05
Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
2003-04-05
Pramipexole in comparison to l-dopa: a neuropsychological study.
2003-04
Slowing Parkinson's disease progression: recent dopamine agonist trials.
2003-02-11
Piribedil-induced sleep attacks in Parkinson's disease.
2003-02
Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
2003-02
Loss of color vision during long-term treatment with pramipexole.
2003-01
Sleepwalking and sleep terrors in prepubertal children: what triggers them?
2003-01
Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease.
2003
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
2003
Advances in the pharmacological management of Parkinson disease.
2003
Inhibitory effects of D2 agonists by striatal injection on excessive release of dopamine and hyperactivity induced by Bay K 8644 in rats.
2003
Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
2003
Dopamine agonists induce episodes of irresistible daytime sleepiness.
2003
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.
2002-12-24
Dopamine agonist monotherapy in Parkinson's disease.
2002-11-30
Restless legs syndrome augmentation and pramipexole treatment.
2002-11
Do dopamine agonists or levodopa modify Parkinson's disease progression?
2002-11
Dopamine agonists and neuroprotection in Parkinson's disease.
2002-11
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
2002-11
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002-11
Neuroprotection in idiopathic Parkinson's disease.
2002-10
Pramipexole in treatment-resistant depression: a 16-week naturalistic study.
2002-10
An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease.
2002-10
Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice.
2002-10
Combination of two different dopamine agonists in the management of Parkinson's disease.
2002-09
[Pramipexole in Parkinson disease. Results of a treatment observation].
2002-08
Restless legs syndrome in the older adult: diagnosis and management.
2002
Sleep disorders in Parkinson's disease: epidemiology and management.
2002
Patents

Patents

JP2006505569A
69
JP2007514770A
77
JP2011526251A
112
JP2012500800A
9
JPH03170425A
3

Sample Use Guides

In Vivo Use Guide
Dosages should be increased gradually from a starting dose of 0.375 mg/day given in three divided doses and should not be increased more frequently than every 5 to 7 days.
Route of Administration: Oral
In Vitro Use Guide
Pramipexole suppressed H2O2-induced ARPE-19 cell death in vitro at concentrations of 10(-6) M or higher.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:59:18 GMT 2025
Edited
by admin
on Mon Mar 31 17:59:18 GMT 2025
Record UNII
3D867NP06J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
EMA EPAR   EP   MI   USP-RS   WHO-DD  
Preferred Name English
PRAMIPEXOLE DIHYDROCHLORIDE
ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
SND-919CL2Y
Code English
SND919CL2Y
Code English
SIFROL
Brand Name English
PRAMIPEXOLE HYDROCHLORIDE MONOHYDRATE
Common Name English
PRAMIPEXOLE TEVA
Brand Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE [EMA EPAR]
Common Name English
PNU-98528E
Code English
PRAMIPEXOLE DIHYDROCHLORIDE [USP MONOGRAPH]
Common Name English
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate
Systematic Name English
MIRAPEX
Brand Name English
PRAMIPEXOLE DIHYDROCHLORIDE [VANDF]
Common Name English
PRAMIPEXOLE ACCORD
Brand Name English
MIRAPEXIN
Brand Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE [USP-RS]
Common Name English
PRAMIPEXOLE HYDROCHLORIDE HYDRATE [JAN]
Common Name English
PRAMIPEXOLE DIHYDROCHLORIDE [USAN]
Common Name English
PRAMIPEXOLE HYDROCHLORIDE [MART.]
Common Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE [EP MONOGRAPH]
Common Name English
PRAMIPEXOLE HYDROCHLORIDE HYDRATE
JAN  
Common Name English
OPRYMEA
Brand Name English
Pramipexole dihydrochloride monohydrate [WHO-DD]
Common Name English
PRAMIPEXOLE DIHYDROCHLORIDE [ORANGE BOOK]
Common Name English
PRAMIPEXOLE HYDROCHLORIDE
MART.  
Common Name English
DAQUIRAN
Brand Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE [MI]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS PRAMIPEXOLE ACCORD (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS MIRAPEXIN (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS PRAMIPEXOLE TEVA (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS SIFROL (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS MIRAPEXIN (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS PRAMIPEXOLE ACCORD (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
NCI_THESAURUS C66884
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS OPRYMEA (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS DAQUIRAN (WITHDRAWN: PARKINSON DISEASE)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS SIFROL (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
NCI_THESAURUS C38149
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID1044227
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
RS_ITEM_NUM
1553859
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
RXCUI
236747
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY RxNorm
CAS
191217-81-9
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
DAILYMED
3D867NP06J
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
ChEMBL
CHEMBL301265
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
CHEBI
51147
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
CHEBI
51148
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
DRUG BANK
DBSALT001198
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
EVMPD
SUB25197
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
NCI_THESAURUS
C29374
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
SMS_ID
100000091470
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
USAN
KK-01
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
EVMPD
SUB12563MIG
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
PUBCHEM
166589
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
FDA UNII
3D867NP06J
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
MERCK INDEX
m9095
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY Merck Index
EVMPD
SUB04004MIG
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
Related Record Type Details
Structure of PRAMIPEXOLE DIHYDROCHLORIDE ANHYDROUS
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of PRAMIPEXOLE
PARENT -> SALT/SOLVATE
Structure of PRAMIPEXOLE DIHYDROCHLORIDE ANHYDROUS
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Structure of PRAMIPEXOLE DIHYDROCHLORIDE ANHYDROUS
ANHYDROUS->SOLVATE
Related Record Type Details
Structure of 1-[[(6S)-4,5,6,7-Tetrahydro-6-(propylamino)-2-benzothiazolyl]amino]methanol
IMPURITY -> PARENT
Structure of PRAMIPEXOLE DIMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2,6-DIAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE, (S)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of PRAMIPEXOLE PROPIONAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of PRAMIPEXOLE DIMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of (6S)-6-N-ETHYL-4,5,6,7-TETRAHYDRO-1,3-BENZOTHIAZOLE-2,6-DIAMINE
IMPURITY -> PARENT
Structure of PRAMIPEXOLE PROPIONAMIDE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of N-Propylpramipexole
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6-N-PROPYL-4,5,6,7-TETRAHYDRO-1,3-BENZOTHIAZOLE-2,6-DIAMINE, (6R)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2,6-DIAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE, (S)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-Propylpramipexole
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-nitroso-pramipexole
IMPURITY -> PARENT
Related Record Type Details
Structure of PRAMIPEXOLE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966